HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Thrombotic stroke and myocardial infarction with hormonal contraception.

AbstractBACKGROUND:
Although several studies have assessed the risk of venous thromboembolism with newer hormonal contraception, few have examined thrombotic stroke and myocardial infarction, and results have been conflicting.
METHODS:
In this 15-year Danish historical cohort study, we followed nonpregnant women, 15 to 49 years old, with no history of cardiovascular disease or cancer. Data on use of hormonal contraception, clinical end points, and potential confounders were obtained from four national registries.
RESULTS:
A total of 1,626,158 women contributed 14,251,063 person-years of observation, during which 3311 thrombotic strokes (21.4 per 100,000 person-years) and 1725 myocardial infarctions (10.1 per 100,000 person-years) occurred. As compared with nonuse, current use of oral contraceptives that included ethinyl estradiol at a dose of 30 to 40 μg was associated with the following relative risks (and 95% confidence intervals) for thrombotic stroke and myocardial infarction, according to progestin type: norethindrone, 2.2 (1.5 to 3.2) and 2.3 (1.3 to 3.9); levonorgestrel, 1.7 (1.4 to 2.0) and 2.0 (1.6 to 2.5); norgestimate, 1.5 (1.2 to 1.9) and 1.3 (0.9 to 1.9); desogestrel, 2.2 (1.8 to 2.7) and 2.1 (1.5 to 2.8); gestodene, 1.8 (1.6 to 2.0) and 1.9 (1.6 to 2.3); and drospirenone, 1.6 (1.2 to 2.2) and 1.7 (1.0 to 2.6), respectively. With ethinyl estradiol at a dose of 20 μg, the corresponding relative risks according to progestin type were as follows: desogestrel, 1.5 (1.3 to 1.9) and 1.6 (1.1 to 2.1); gestodene, 1.7 (1.4 to 2.1) and 1.2 (0.8 to 1.9); and drospirenone, 0.9 (0.2 to 3.5) and 0.0. For transdermal patches, the corresponding relative risks were 3.2 (0.8 to 12.6) and 0.0, and for a vaginal ring, 2.5 (1.4 to 4.4) and 2.1 (0.7 to 6.5).
CONCLUSIONS:
Although the absolute risks of thrombotic stroke and myocardial infarction associated with the use of hormonal contraception were low, the risk was increased by a factor of 0.9 to 1.7 with oral contraceptives that included ethinyl estradiol at a dose of 20 μg and by a factor of 1.3 to 2.3 with those that included ethinyl estradiol at a dose of 30 to 40 μg, with relatively small differences in risk according to progestin type. (Funded by the Danish Heart Association.).
AuthorsØjvind Lidegaard, Ellen Løkkegaard, Aksel Jensen, Charlotte Wessel Skovlund, Niels Keiding
JournalThe New England journal of medicine (N Engl J Med) Vol. 366 Issue 24 Pg. 2257-66 (Jun 14 2012) ISSN: 1533-4406 [Electronic] United States
PMID22693997 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Contraceptive Agents
  • Contraceptives, Oral, Combined
  • Progestins
  • Estradiol
Topics
  • Administration, Cutaneous
  • Adolescent
  • Adult
  • Cohort Studies
  • Contraceptive Agents (adverse effects)
  • Contraceptives, Oral, Combined (adverse effects)
  • Educational Status
  • Estradiol (administration & dosage, adverse effects)
  • Female
  • Humans
  • Incidence
  • Intracranial Thrombosis (chemically induced, epidemiology)
  • Middle Aged
  • Myocardial Infarction (chemically induced, epidemiology)
  • Progestins (administration & dosage, adverse effects)
  • Regression Analysis
  • Risk
  • Smoking (adverse effects)
  • Stroke (chemically induced, epidemiology)
  • Thrombosis
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: